Sagility Limited (SAGILITY) Fair Value & Analysis
Healthcare · IN · Market cap ₹192B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price +2.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹36.35 – ₹54.53 · fair‑value band ₹29.63 – ₹49.39 · the ₹40.98 price screens above the ₹39.51 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Sagility Limited (SAGILITY) currently trades at ₹40.98, while our model-based Fair Value estimate is ₹39.51 — implying the stock looks roughly 3.6% overvalued today. We read business quality at 56/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Sagility Limited generated revenue of ₹71.9B at a net margin of 12.9%. Revenue grew 29.1% year over year. It earns a return on equity of 10.3%. Net debt stands at ₹5.4B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Sagility Limited engages in the provision of business process management services to the healthcare and insurance industries in India, Jamaica, the Philippines, the United States, and Colombia. The company offers claims cost containment and management, member and provider engagement, enrolment, benefits plan building, payment integrity and billing, credentialing, clinical and case management, provider network operation services, analytics, front and back-office, administrative support provider, and data management services. It also provides utilization and care management, and population health management, as well as revenue cycle management functions, such as financial clearance, medical coding, billing, labs and durable medical equipment support, patient access and engagement, and accounts receivable follow-up services. In addition, it provides services to pharmacy benefit managers that manage prescription drugs for members under health insurance plans. Further, it offers various …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Sagility Limited reported revenue of ₹71.9B in FY2026 versus ₹13.9B in FY2022, a compound +51.0%/yr. Reported net income was ₹9.2B in FY2026.
Is SAGILITY fairly valued? → Check now
Similar stocks
6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $153.16 | $183.66 | +20% |
| Pro Medicus Limited PME | A$165.64 | A$28.02 | -83% |
| BrightSpring Health Services, Inc BTSG | $60.59 | $23.87 | -61% |
| Tempus AI, Inc TEM | $48.61 | $12.67 | -74% |
| HealthEquity, Inc HQY | $84.61 | $79.57 | -6% |
| M3, Inc MTHRY | $5.21 | $7.47 | +43% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sagility Limited (SAGILITY) undervalued?
What is the fair value of SAGILITY?
What is the quality score of SAGILITY?
What is the revenue of Sagility Limited (SAGILITY)?
What is the net profit margin of SAGILITY?
Does Sagility Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.